WO2006081452A3 - Co-administration of perifosine with chemotherapeutics - Google Patents

Co-administration of perifosine with chemotherapeutics Download PDF

Info

Publication number
WO2006081452A3
WO2006081452A3 PCT/US2006/002988 US2006002988W WO2006081452A3 WO 2006081452 A3 WO2006081452 A3 WO 2006081452A3 US 2006002988 W US2006002988 W US 2006002988W WO 2006081452 A3 WO2006081452 A3 WO 2006081452A3
Authority
WO
WIPO (PCT)
Prior art keywords
perifosine
administration
chemotherapeutics
chemotherapeutic agent
trastuzumab
Prior art date
Application number
PCT/US2006/002988
Other languages
French (fr)
Other versions
WO2006081452A2 (en
Inventor
Robert Birch
Isaac Craig Hendersen
Original Assignee
Robert Birch
Isaac Craig Hendersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Birch, Isaac Craig Hendersen filed Critical Robert Birch
Publication of WO2006081452A2 publication Critical patent/WO2006081452A2/en
Publication of WO2006081452A3 publication Critical patent/WO2006081452A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

The present invention is directed to methods of treating cancer by co-administration of perifosine and a second chemotherapeutic agent, which second chemotherapeutic agent includes, but is not limited to, paclitaxel, docetaxel, gemcitabine and trastuzumab.
PCT/US2006/002988 2005-01-28 2006-01-27 Co-administration of perifosine with chemotherapeutics WO2006081452A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64808005P 2005-01-28 2005-01-28
US60/648,080 2005-01-28

Publications (2)

Publication Number Publication Date
WO2006081452A2 WO2006081452A2 (en) 2006-08-03
WO2006081452A3 true WO2006081452A3 (en) 2007-11-22

Family

ID=36741087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002988 WO2006081452A2 (en) 2005-01-28 2006-01-27 Co-administration of perifosine with chemotherapeutics

Country Status (1)

Country Link
WO (1) WO2006081452A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
KR20130016413A (en) 2002-07-30 2013-02-14 아에테르나 젠타리스 게엠베하 A drug product of alkylphosphocholines in combination with antitumor medicaments
KR101378005B1 (en) * 2005-12-19 2014-03-27 아에테르나 젠타리스 게엠베하 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097470A1 (en) * 2002-07-30 2004-05-20 Jurgen Engel Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097470A1 (en) * 2002-07-30 2004-05-20 Jurgen Engel Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals

Also Published As

Publication number Publication date
WO2006081452A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2007053573A3 (en) Treatment of cancer with sorafenib
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2006113703A3 (en) Carboline derivatives useful in the treatment of cancer
WO2008109440A8 (en) Predicting response to a her dimerisation inhibitor based on low her3 expression
MX2009006536A (en) Organic compounds and their uses.
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
EP2103628A4 (en) Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
NO20091661L (en) Use of pegylated IL-10 to treat cancer
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
EP1942884A4 (en) Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
MY150493A (en) Quinazoline derivatives
CA119816S (en) Manikin chest shield
WO2007061922A3 (en) Methods to predict and prevent resistance to taxoid compounds
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2007053284A3 (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
WO2009152210A3 (en) Coumarin compounds and their use for treating cancer
WO2008070743A3 (en) Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35
TNSN08496A1 (en) Aminothiazoles and their uses
WO2008137128A3 (en) Methods of treating fungal infections
WO2006081452A3 (en) Co-administration of perifosine with chemotherapeutics
WO2010037095A3 (en) Agents and methods for the treatment of cancer
MX2009009693A (en) Methods of activating irs-1 and akt.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 06719713

Country of ref document: EP

Kind code of ref document: A2